^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    izastobart (HIB210)

    i
    Other names: WBP-2191, HIB210, MOR210, TJ210, WBP2191, MOR044254, TJ210001, HIB 210, HIB-210, MOR 044254, MOR-044254, MOR 210, MOR-210, TJ-210, TJ 210, TJ 210001, TJ-210001, WBP 2191
    Associations

    News

    Trials
    Company:
    Biogen, Novartis
    Drug class:
    C5aR inhibitor
    Related drugs:
    Associations

    News

    Trials
    3years
    Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=16, Completed, I-Mab Biopharma Co. Ltd. | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    izastobart (HIB210)
    over3years
    Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, I-Mab Biopharma Co. Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Mar 2022 --> Feb 2023 | Trial primary completion date: Sep 2021 --> Oct 2022
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    izastobart (HIB210)
    5years
    Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=16, Recruiting, I-Mab Biopharma Co. Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    izastobart (HIB210)
    5years
    Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, I-Mab Biopharma Co. Ltd.
    Clinical • New P1 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    izastobart (HIB210)